How many drugs treat Parkinson's disease?

Drug Landscape tracks 10 marketed treatments for Parkinson's disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Parkinson's disease?

Most recent: FOSLEVODOPA — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/parkinson-s-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Parkinson's disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Parkinson's disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Parkinson's disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
FOSCARBIDOPA	FOSCARBIDOPA	AbbVie GK			2024-01-01
FOSLEVODOPA	FOSLEVODOPA	AbbVie GK			2024-01-01
Ongentys	BIA 9-1067	Neurocrine Biosciences	Catechol-O-Methyltransferase Inhibitor [EPC]	Catechol O-methyltransferase	2020-01-01
Nourianz	ISTRADEFYLLINE	Kyowa Kirin	CYP3A4 Substrates	Adenosine receptor A2a	2019-01-01
Xadago	SAFINAMIDE	Mdd Us	Monoamine Oxidase Type B Inhibitor	Amine oxidase [flavin-containing] B	2017-01-01
Nuplazid	PIMAVANSERIN	Acadia Pharms Inc	Atypical Antipsychotic	5-hydroxytryptamine receptor 2A	2016-01-01
Northera	DROXIDOPA	Lundbeck Na Ltd	Catecholamine	Muscarinic acetylcholine receptor M1	2014-01-01
Neupro	ROTIGOTINE	UCB	Nonergot Dopamine Agonist [EPC]	dopamine receptors	2007-01-01
Azilect	RASAGILINE	Teva	Monoamine Oxidase Inhibitor	5-hydroxytryptamine receptor 6	2006-01-01
Apokyn	APOMORPHINE	Mdd Us	Non-Standardized Plant Allergenic Extract [EPC]	D(2) dopamine receptor	2004-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-19 — FOSLEVODOPA · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Parkinson's disease
Mdd Us · 2 drugs in Parkinson's disease
AbbVie GK · 2 drugs in Parkinson's disease
Baylor College of Medicine · 1 drug in Parkinson's disease
Esjay Pharma · 1 drug in Parkinson's disease
Bial - Portela C S.A. · 1 drug in Parkinson's disease
Aton · 1 drug in Parkinson's disease
Centre Hospitalier Universitaire de Nice · 1 drug in Parkinson's disease
Eli Lilly · 1 drug in Parkinson's disease
Endo · 1 drug in Parkinson's disease
Boehringer Ingelheim · 1 drug in Parkinson's disease
Acadia Pharms Inc · 1 drug in Parkinson's disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Parkinson's disease:

Cite this brief

Drug Landscape (2026). Parkinson's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/parkinson-s-disease. Accessed 2026-06-10.

Parkinson's disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing